Dr. Rosenzweig Discusses Emerging Agents in Amyloidosis

Michael Rosenzweig, MD
Published: Thursday, Apr 26, 2018



Michael Rosenzweig, MD, assistant professor in the department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses emerging agents in the treatment of patients with amyloidosis.

The standard approach to the treatment of amyloidosis is to attack the underlying small plasma cell clone that is responsible for the light chains that are producing amyloid and then depositing it in organs and tissues. The progress that has been made in developing therapies for amyloidosis goes hand-in-hand with the progress that has been made in multiple myeloma, says Rosenzweig.

Daratumumab (Darzalex) is an exciting new drug for relapsed myeloma, which is moving up to the frontline. It has also been studied in amyloidosis and has been found to be very effective, Rosenzweig says. There is a novel anti-amyloid fibril therapy under investigation in clinical trials called NEOD001, and another that is in earlier stages called 111F4. Both have shown preliminary signals of efficacy in patients with amyloidosis.


Michael Rosenzweig, MD, assistant professor in the department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses emerging agents in the treatment of patients with amyloidosis.

The standard approach to the treatment of amyloidosis is to attack the underlying small plasma cell clone that is responsible for the light chains that are producing amyloid and then depositing it in organs and tissues. The progress that has been made in developing therapies for amyloidosis goes hand-in-hand with the progress that has been made in multiple myeloma, says Rosenzweig.

Daratumumab (Darzalex) is an exciting new drug for relapsed myeloma, which is moving up to the frontline. It has also been studied in amyloidosis and has been found to be very effective, Rosenzweig says. There is a novel anti-amyloid fibril therapy under investigation in clinical trials called NEOD001, and another that is in earlier stages called 111F4. Both have shown preliminary signals of efficacy in patients with amyloidosis.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Oncology Briefings™: Updates in Rare Hematology: Advancing Care and Improving Outcomes for Patients with Aplastic AnemiaAug 31, 20181.0
Publication Bottom Border
Border Publication
x